Vaccines for Enteric Diseases

8-10 July 2015, The Royal College of Physicians of Edinburgh, Edinburgh, UK

  • Increase font size
  • Default font size
  • Decrease font size

Day Two

Final Conference Programme | Thursday 9th July 2015

SESSION 5:
FRONTIERS IN ENTERIC VACCINOLOGY

Moderators: Dani Cohen (Tel Aviv University, Tel Aviv, Israel) and Tom Wierzba (PATH, Washington DC, USA)

08.30-08.50
‘Clayton Harro Memorial Lecture’

‘Protective efficacy of an enterotoxigenic E. coli fimbrial tip adhesin vaccine given with LTR192G by intradermal vaccination against experiment challenge with CFA/I-ETEC in adult volunteers’
C. Harro 1, R. Gutierrez 2, M. Riddle 2, C. Porter 2, M. Maciel 2, S. Poole 2, R. Laird 2 and S. Savarino 2 (1 Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA; 2 Naval Medical Research Center, Silver Spring, Maryland, USA)

08.50-09.10
‘Enteric vaccines adjuvants: Overview and mechanism of action of enterotoxin-derived adjuvants’
Jan Holmgren, Maximilian Larena, Michael Lebens, Anna Lundgren and Manuela Terranoni (University of Gothenburg, Gothenburg, Sweden)

09.10-09.30
‘Physiologic and immunologic consequences of exposure to ETEC enterotoxins’
Lisa T. Read, Rachel W. Hahn, Carli C. Thompson, David L. Bauer, Elizabeth B. Norton, Jacob P. Bitoun, and John D. Clements (Tulane University School of Medicine, New Orleans, Louisana, USA)

09.30-09.50
‘Experimental ETEC infections: Going beyond the ‘running stool log’
Chad K. Porter 1, Mark S. Riddle 1, Ashley N. Alcala 1, David R. Tribble 2, David Sack 3, Clayton Harro 3, Subhra Chakraborty 3, Ramiro L. Gutierrez 1, Stephen J. Savarino 1, Mike Darsley 4, Robin McKenzie 3, Anne Berit Guttormsen 6, Hans Steinsland 6 and A. Louis Bourgeois 5 (1 Naval Medical Research Center, Silver Spring, Maryland, USA; 2 Infectious Disease Clinical Research Program, Bethesda, Maryland, USA; 3 Johns Hopkins University, Baltimore, Maryland, USA; 4 MD Biologic, LTD, Cambridge, Massachusetts, USA; 5 PATH, Washington, DC, USA; 6 University of Bergen, Bergen, Norway)

09.50-10.10
‘The novel oral vaccine delivery technology SmPill® significantly increases vaccine-specific intestinal antibody responses’
Stephanie Longet 1, Christopher Davitt 1, Edel McNeela 1, Vincenzo Aversa 3, Joshua Tobias 2, Michael Lebens 2, Monica Rosa 3, Jan Holmgren 2, Ivan Coulter 3 and Ed C. Lavelle 1 (1 Trinity College Dublin, Dublin, Ireland; 2 University of Gothenburg, Gothenburg, Sweden; 3 Dublin City University, Dublin, Ireland)

10.10-10.30
‘Understanding pathogen behaviour in vivo for the rational design of safer live attenuated bacterial vaccines’
Andrew Grant, Chris Coward, Sarah Peters, Olivier Restif, Richard Dybowski, Olusegun Oshota, Simon Clare, Gordon Dougan, Duncan Maskell and Pietro Mastroeni (Department of Veterinary Medicine, University of Cambridge, United Kingdom/Wellcome Trust Sanger Institute, Hinxton, United Kingdom)

10.30 -10.50
Coffee Break & Posters

SESSION 6:
COMBINED VACCINES

Moderators: Richard Walker (PATH, Washington DC, USA) and Melody Mills (NIH/NIAID, Bethesda, Maryland, USA)

10.50-11.10
‘Advances in the development of a combined Shigella-ETEC vaccine’
Eileen Barry, Tao Wu, Christen Grassel and Myron Levine (Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA)

11.10-11.30
‘ShigETEC™, a live attenuated vaccine inducing serotype independent protection against Shigella and immune response against ETEC toxins’
Shushan Harutyunyan, Michael Aichinger, Petra Krause, Valéria Szijártó, Gábor Nagy, Eszter Nagy and Tamás Henics (EveliQure Biotechnologies GmbH, Vienna, Austria)

11.30-11.50
‘Chromosomal super-recombineering in development of an oral vaccine for simultaneous protection against both enteric fevers and Shigellosis’
Madushini N. Dharmasena 1, Manuel Osorio 1, Scott Stibitz 1 and Dennis J. Kopecko 1,2 (1 U.S. FDA-Center for Biologics Evaluation and Research, Silver Spring, Maryland, USA; 2 Protein Potential, LLC, Rockville, Maryland, USA)

11.50-12.00
‘Development of a live attenuated vaccine against typhoid fever and shigellosis’
Yun Wu, Sumana Chakravarty, Minglin Li, Tint Tint Wai, Dennis J. Kopecko, Stephen L. Hoffman and B. Kim Lee Sim (Protein Potential LLC, Rockville, Maryland, USA

12.00-12.20
‘ETEC-C. jejuni Capsule Conjugate Vaccine Immunogenicity and Protective Efficacy in A. nancymaae
Nathanael D. Reynolds 1, Amritha Ramakrishnan 1, Mark P. Simons 1, Nelum Dorabawila 2, Zuchao Ma 3, Alexander Maue 2, Renee Laird 2, Steven Poole 2, Yang Liu 2, Milton Maciel Jr. 2, Mario A. Monteiro 3, Stephen J. Savarino 2 and Patricia Guerry 2 (1 Naval Medical Research Unit 6, Lima, Peru; 2 Naval Medical Research Center, Silver Spring, Maryland, USA; and 3 University of Guelph, Guelph, Ontario, Canada)

12.20-12.40
‘Development of Typhetec®: An oral typhoid-ETEC vaccine’
Rocky Cranenburgh (Prokarium Ltd, Keele Science Park, Keele, Staffordshire UK)

12.40-13.30
Lunch Break & Posters

SESSION 7:
NEGLECTED ENTERIC PATHOGENS

Moderators: Beth Kirkpatrick (University of Vermont, Burlington, Vermont, USA)

13.30-13.50
‘Invasive Salmonella infections in Africa and implications for vaccination programs’
Florian Marks et al. (International Vaccine Institute, Seoul, Korea)

13.50-14.10
‘Utility of a Cryptosporidium human challenge model as a platform to guide development of vaccines and therapeutics’
C.E. Lyon, C.D. Huston, M. Carmolli, S.A. Diehl, E.R. Colgate and B.D. Kirkpatrick (University of Vermont, Burlington, Vermont, USA)

14.10-14.20
‘Safety and immunogenicity of a Campylobacter capsule-conjugate vaccine in healthy adult volunteers’
R. Gutierrez 1, R Gormley 1, M. Riddle 1, C. Porter 1, K. Paolino 2, A. Maue1, R. Laird 1, N. Dorabawila 1, K. Jaep 1, A. Castellano 2, M. Monteiro 3 and P. Guerry 1 (1 Naval Medical Research Center, Silver Spring, Maryland, USA; 2 Walter Reed Army Institute of Research Clinical Trials Center, Silver Spring, Maryland, USA; 3 University of Guelph, Guelph, Ontario, Canada)

14.20-14.40
‘Vaccines against Campylobacter jejuni based on polysaccharide capsules’
Patricia Guerry 1, Yuening Jiao 2, Nelum Dorabawilla 1 and Mario A. Monteiro 2 (1 Naval Medical Research Center, Silver Spring, Maryland, USA; 2 University of Guelph, Guelph, Ontario, Canada)

14.40-15.00
Helicobacter pylori infection in early childhood and growth at school age’
Khitam Muhsen, Sophy Goren and Dani Cohen (Tel Aviv University, Tel Aviv University, Israel)

15.00-15.20
Tea Break & Posters

SESSION 8:
CHOLERA

Moderators: David A. Sack (Johns Hopkins University, Baltimore, Maryland, USA) and Robert Hall (NIAID/NIH, Bethesda, Maryland, USA)

15.20-15.40
‘Update on the developments of OCV with regard to stockpile, GAVI and use of vaccine in outbreaks’
Dominique Legros (WHO Global Cholera Task Force, Geneva, Switzerland)

15.40-16.00
‘Characterizing the regional distribution and burden of cholera in Africa’
Sean M. Moore, Andrew S. Azman and Justin Lessler (Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA)

16.00-16.20
‘Clinical and environmental surveillance for Vibrio Cholerae in resource constrained areas: Application during a one year surveillance in the far north region of Cameroon’
Amanda K. Debes, Jerome Ateudjieu, Walter Ebile, Malathi Ram, Etienne Guenou and David Sack (Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA)

16.20-16.35
‘Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell oral cholera vaccine in the Philippines: Results of the first Asian study outside the Indian subcontinent’
Naveena Aloysia 1, Yael Thollot 2, Maria Rosario Capeding 3, Ma. Liza Antoinette Gonzales 4, Anvar Rasuli and Mandeep Dhingra 1 (1 Shantha Biotechnics Ltd, Hyderabad, India; 2 Sanofi Pasteur, Lyon, France; 3 Research Institute for Tropical Medicine, Muntinlupa City, Philippines; 4 Philippine General Hospital-University of the Philippines, Manila, Philippines)

16.35-16.50
‘Is the use of a single dose of killed whole cell oral cholera vaccine justified in response to outbreaks?’
Andrew S. Azman 1,3, Francisco J. Luquero 2,4, Iza Ciglenecki 3, Rebecca F. Grais 2, David A. Sack 4 and Justin Lessler 1 (Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA; 2 Epicentre, Paris, France; 3 Médecins Sans Frontières, Geneva, Switzerland; 4 Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA)

16.50-17.05
‘Oral cholera vaccine use in South Sudan, 2014’
Abdinasir Abubakar 1, Francisco J. Luquero 2, Andrew S. Azman 3, Iza Ciglenecki 4, Trina Helderman 5, Haley West 6, John Rumono 7, Stephen Martin 8 and Dominique Legros 8 (1 World Health Organization, Juba, Republic of South Sudan; 2 Epicentre, Paris, France; 3 Johns Hopkins University, DOVE Project, Baltimore, USA; 4 Médecins Sans Frontières, Geneva, Switzerland; 5 Medeair, Geneva, Switzerland; 6 International Organization for Migration, Juba, Republic of South Sudan; 7 Ministry of Health, Juba, Republic of South Sudan; 8 World Health Organization, Geneva, Switzerland)

17.05-17.20
‘Redevelopment of a single-dose live-attenuated oral cholera vaccine CVD 103-HgR’
Jakub K. Simon 1, Wilbur H. Chen 2, Mitchell B. Cohen 3, Beth D. Kirkpatrick 4, Caroline E. Lyon 4, Robert H. Hall 5, Michael Lock 1, Myron M. Levine 2 and Marc Gurwith 1 (1 PaxVax, Inc., Redwood City, California, USA; 2 University of Maryland School of Medicine, Baltimore, Maryland, USA; 3 Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; 4 University of Vermont College of Medicine, Burlington, Vermont, USA; 5 National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA)

17.20-17.35
‘Development of a '2nd generation' vaccine for epidemic response and endemic country use’
Marc Gurwith 1, Jakub K. Simon 1, Wilbur H. Chen 2, Mitchell B. Cohen 3, Beth D. Kirkpatrick 4, Caroline E. Lyon 4, Robert H. Hall 5, Michael Lock 1 and Myron M. Levine 2 (1 PaxVax, Inc., Redwood City, California, USA; 2 University of Maryland School of Medicine, Baltimore, Maryland, USA; 3 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA; 4 University of Vermont College of Medicine, Burlington, Vermont, USA; 5 National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA)

17.35-17.50
‘Validity of the estimates of cholera vaccine protective effectiveness derived from the test-negative design’
Mohammad Ali, Young Ae You, Dipika Sur, Suman Kanungo, Deok Ryun Kim, Jacqueline L. Deen, Lorenz von Seidlein, Thomas F. Wierzba, Sujit K. Bhattacharya and John D. Clemens (Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA)

17.50-18.05
‘AfriChol, the African Cholera Surveillance Network understanding the distribution of cholera burden in Africa and its usefulness for determining vaccine impact’
Martin Mengel (Agence de Medecine Preventive, AMP, Paris, France)

18.05-18.25
‘Update of recent studies on oral cholera vaccine in Bangladesh and prospects for the future’
Firdausi Qadri and John Clemens et al. (ICDDR, Dhaka, Bangladesh)

Free Evening for VED 2015 Delegates

 

VED 2015 Sponsors

  • DNAvaccine.com
  • hVIVO
  • BioVaxx
  • NatureGeneTherapy.com
  • Matrivax
  • Takeda
  • GlycoVaxyn
  • Sanofi Pasteur
  • PATH
  • Vaccine Research Center
  • Aldevron
  • Eveliqure

VED 2015 Downloads

VED 2015 Leaflet

VED 2015 Mailing List

Name
E-mail Address
What is 6+3-1?